Quantum dot-aptamer conjugates for synchronous cancer imaging, therapy, and sensing of drug delivery based on bi-fluorescence resonance energy transfer.

By Vaishali Bagalkot, Liangfang Zhang, E. Levy-Nissenbaum, S. Jon, P. Kantoff, Robert Langer, O. Farokhzad. Nano letters (Print), 2007

916 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Cancer active targeting by nanoparticles: a comprehensive review of literature (2014, methodology): “Bagalkot et al. (2007) reported targeting multifunctional quantum dot-doxorubicin using the A10 RNA aptamer.”
Surface modification, functionalization and bioconjugation of colloidal inorganic nanoparticles (2010, background): “…organic molecules (Mulder et al. 2006a; Bakalova et al. 2007) or non-fluorescent nanoparticles with fluorescent dyes (Bertorelle et al. 2006; Bagalkot et al. 2007; Kim et al. 2008a; Liong et al. 2008), bio-functional molecules (Schellenberger et al. 2004; Herr et al. 2006; Garanger et al.…”
Nanoparticles for Cancer Therapy: Current Progress and Challenges (2021, background): “For example, quantum dots aptamer – doxorubicin conjugate targets prostate cancer cells [98].”
Innovative approaches for cancer treatment: current perspectives and new challenges (2019, methodology): “The same aptamer has been also used to prepare quantum dot-doxorubicin conjugates [144].”
Targeting Strategies for Multifunctional Nanoparticles in Cancer Imaging and Therapy (2012, methodology): “meric nanoparticles [118-120], and QDs [121].”